{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T03:23:14Z","timestamp":1788751394836,"version":"build-2803163510"},"reference-count":0,"publisher":"Harborside Press, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JADPRO"],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:p>Introduction: Despite standard prevention strategies, obinutuzumab carries a significant risk of infusion-related reactions (IRRs) for patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). Reported rates of IRRs vary in phase III clinical trials evaluating obinutuzumab-containing regimens. Although obinutuzumab has a higher rate of severe (grade 3 and higher) IRRs than rituximab, clinical risk factors predicting IRR have not been identified, and therefore strata informing patient-specific risk of IRR have not been applied in practice. Methods: This multicenter, retrospective evaluation of patients with CLL\/SLL estimated the incidence of obinutuzumab-related IRRs and evaluated risk factors for the development of IRR in a real-world population. Results: 68 patients with untreated or previously treated CLL\/SLL were included in the analysis, with the majority being older adult (median age = 70) males (61.8%) with Rai stage III and IV CLL. All-grade IRRs occurred in 25% of patients, and severe IRRs occurred in 1.5% of patients. Of the variables evaluated, absolute lymphocyte count was a significant predictor (p \u2264 .05) of the odds of experiencing an IRR in patients receiving obinutuzumab. Conclusion: Obinutuzumab IRR rates in a real-world population were comparable to most phase III clinical trial results succeeding implementation of split dosing and standard premedication. Absolute lymphocyte count is a statistically significant predictor for increased odds of experiencing an IRR. Future research evaluating risk-adapted obinutuzumab administration strategies is needed to recommend a specific approach.<\/jats:p>","DOI":"10.6004\/jadpro.2024.15.7.2","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T20:35:52Z","timestamp":1732653352000},"page":"437-443","source":"Crossref","is-referenced-by-count":5,"title":["Obinutuzumab Infusion-Related Reactions: Multicenter Retrospective Evaluation of Incidence, Severity, and Risk Factors"],"prefix":"10.6004","volume":"15","author":[{"given":"Erin","family":"Hickey Zacholski, PharmD, BCOP","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rugh, PharmD Candidate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Marshall, PharmD Candidate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramit","family":"Nadpara, PhD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"C. Moore, PharmD, BCOP, DPLA, FCCP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","published-online":{"date-parts":[[2021,11,1]]},"container-title":["Journal of the Advanced Practitioner in Oncology"],"original-title":[],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T20:35:54Z","timestamp":1732653354000},"score":1,"resource":{"primary":{"URL":"https:\/\/jadpro.com\/issues\/volume-15-number-7-novdec-2024\/obinutuzumab-infusion-related-reactions-multicenter-retrospective-evaluation-of-incidence-severity-and-risk-factors\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":0,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,11,1]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.6004\/jadpro.2024.15.7.2","relation":{},"ISSN":["2150-0878"],"issn-type":[{"value":"2150-0878","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,1]]}}}